Supernus Pharmaceuticals Inc (NASDAQ:SUPN) saw unusually large options trading on Tuesday. Stock traders bought 2,740 put options on the stock. This represents an increase of 3,413% compared to the average volume of 78 put options.
Shares of NASDAQ:SUPN traded up $0.54 on Thursday, reaching $42.78. The company had a trading volume of 299,377 shares, compared to its average volume of 567,922. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $2.21 billion, a PE ratio of 33.95 and a beta of 0.92. Supernus Pharmaceuticals has a 52-week low of $34.90 and a 52-week high of $61.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. The firm had revenue of $102.99 million during the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.29 EPS. Research analysts predict that Supernus Pharmaceuticals will post 1.87 EPS for the current year.
Institutional investors have recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its position in shares of Supernus Pharmaceuticals by 3.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after purchasing an additional 20,012 shares in the last quarter. Icon Advisers Inc. Co. acquired a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth $3,877,000. Oppenheimer Asset Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 9.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after purchasing an additional 1,251 shares in the last quarter. Cynosure Advisors LLC boosted its position in shares of Supernus Pharmaceuticals by 55.0% in the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock worth $494,000 after purchasing an additional 2,930 shares in the last quarter. Finally, SevenBridge Financial Group LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $113,000. 97.83% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have commented on SUPN shares. Jefferies Financial Group raised their price objective on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. Cantor Fitzgerald set a $56.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 8th. ValuEngine upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. Mizuho started coverage on Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price target on the stock. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 12th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $56.00.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Featured Story: Intrinsic Value
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.